Another potential pathway, currently in early clinical development, is the inhibition of colony-stimulating factor receptor 1 (CSF-1R), which controls macrophage differentiation and alters the bone–tumor microenvironment (NCT02472275, NCT02265536). The gene discussed is CSF1R; the disease is neoplasm.